92 related articles for article (PubMed ID: 32691726)
1. Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro.
Semba Y; Akiyoshi T; Hibino H; Imaoka A; Ohtani H
Int J Clin Pharmacol Ther; 2020 Oct; 58(10):539-542. PubMed ID: 32691726
[TBL] [Abstract][Full Text] [Related]
2. Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.
Akiyoshi T; Ishiuchi M; Imaoka A; Ohtani H
Drug Metab Pharmacokinet; 2015 Aug; 30(4):321-4. PubMed ID: 26195224
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Fang P; Zheng X; He J; Ge H; Tang P; Cai J; Hu G
Drug Des Devel Ther; 2017; 11():1283-1290. PubMed ID: 28461741
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T; Kijima T; Otani Y; Nonen S; Namba Y; Mori M; Yokota S; Minami S; Komuta K; Uchida J; Imamura F; Furukawa M; Tsuruta N; Fujio Y; Azuma J; Tachibana I; Kumanogoh A
Clin Lung Cancer; 2013 Sep; 14(5):502-7. PubMed ID: 23664723
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
7. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
[TBL] [Abstract][Full Text] [Related]
8. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y; Morita S; Sugawara S; Kato T; Fukuhara T; Gemma A; Takahashi K; Fujita Y; Harada T; Minato K; Takamura K; Hagiwara K; Kobayashi K; Nukiwa T; Inoue A;
J Clin Oncol; 2020 Jan; 38(2):115-123. PubMed ID: 31682542
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
11. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
12. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
14. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
[TBL] [Abstract][Full Text] [Related]
15. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi H; Sato K; Niioka T; Takeda M; Okuda Y; Asano M; Ito H; Miura M
Med Oncol; 2016 Jun; 33(6):57. PubMed ID: 27154635
[TBL] [Abstract][Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Saito T; Gutiérrez Rico EM; Kikuchi A; Kaneko A; Kumondai M; Akai F; Saigusa D; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Dec; 33(6):250-257. PubMed ID: 30366777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
